Company intelligence
Agomab
Unlocking Disease Modification in Fibro-Inflammation
About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.
Verified activity
Signals from Agomab
5 published signals
Presence & Recognition
Agomab is attending the ERSCongress in Barcelona.
Reported by Agomab
Presence & Recognition
Agomab is attending Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16, 2026.
Reported by Agomab
Presence & Recognition
Agomab is attending H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026.
Reported by Agomab
Presence & Recognition
Agomab is attending Citi's 2026 Biopharma Back to School Conference in New York on September 10, 2026.
Reported by Agomab
Presence & Recognition
Agomab is attending 2026 Cantor Global Healthcare Conference in New York on September 11, 2026.
Reported by Agomab